Reuter C, Auf der Landwehr U, Schleyer E, Zühlsdorf M, Ameling C, Rolf C, Wörmann B, Büchner T, Hiddemann W
Department of Internal Medicine, Georg-August-Universität, Göttingen, Germany.
Leukemia. 1994 Feb;8(2):217-25.
The current study investigated the effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on the intracellular metabolism and cytotoxicity of 1-beta-D-arabinofuranosylcytosine (araC) in leukemic cells of 45 patients with acute myeloid leukemia (AML). AML blasts from bone marrow (BM) (n = 39) and peripheral blood (PB) (n = 17) were incubated for 48 h with or without GM-CSF (100 U/ml) followed by a concurrent treatment with increasing concentrations of araC (0.06-100 microM) for an additional 24 h. After GM-CSF a 1.5-8.4-fold (median 2.3) increase in 3H-araC incorporation into the DNA was observed in ten of 14 peripheral blast specimens and in 23 of 28 bone marrow samples, 18 of whom also showed an enhanced 3H-TdR incorporation (1.5-8.5-fold, median 2.0-fold). Four different types of response were identified when analyzing 3H-araC incorporation into the DNA of bone marrow samples in relation to the applied araC dose: (i) 8/28 cases had increases of the araC incorporation at all araC dose levels applied (0.06-100 microM), (ii) 12/28 at low araC concentrations only (0.06-1.0 microM), (iii) 3/28 at high araC concentrations only (10-100 microM), and (iv) 5/28 showed no increase at any dose level given. Hence, 20 of the 23 responding patients revealed a GM-CSF induced enhancement of araC incorporation at low or conventional doses of araC (0.06-1.0 microM). Fourteen of the 18 cases with concomitant rises of 3H-TdR and 3H-araC incorporation into the DNA after GM-CSF had elevated DNA polymerase alpha activity (16-531%, median 72%) and in ten cases overall DNA polymerase activity was enhanced (10-70%, median 22.5%). In contrast, thymidine kinase (TK) and deoxycytidine kinase (dCK) activity were elevated after GM-CSF in only ten and five patients, respectively. An increase in the fraction of cells in S phase was found in 11/21 bone marrow specimens and in 5/9 peripheral blast samples. However, no correlation was observed between increases in the proportion of cells in S phase and enhancements in enzyme activities. In 13 cases the cytotoxicity of araC with and without GM-CSF was assessed by means of a blast cell colony assay. Preincubation with GM-CSF increased the araC mediated cytotoxicity in ten of 13 patients by a median of 3.2-fold (range 2.2-229-fold). The respective LD50 values for araC were reduced from 0.45 to 0.19 microM on average.(ABSTRACT TRUNCATED AT 400 WORDS)
本研究调查了粒细胞-巨噬细胞集落刺激因子(GM-CSF)对45例急性髓系白血病(AML)患者白血病细胞中1-β-D-阿拉伯呋喃糖基胞嘧啶(araC)的细胞内代谢及细胞毒性的影响。将来自骨髓(BM)(n = 39)和外周血(PB)(n = 17)的AML原始细胞在有或无GM-CSF(100 U/ml)的情况下孵育48小时,随后用浓度递增的araC(0.06 - 100 μM)同时处理24小时。加入GM-CSF后,在14份外周原始细胞标本中的10份以及28份骨髓样本中的23份中,观察到3H-araC掺入DNA增加了1.5 - 8.4倍(中位数为2.3倍),其中18份样本还显示3H-胸苷掺入增加(1.5 - 8.5倍,中位数为2.0倍)。在分析骨髓样本中3H-araC掺入DNA与所应用的araC剂量的关系时,确定了四种不同类型的反应:(i)28例中有8例在所有应用的araC剂量水平(0.06 - 100 μM)下araC掺入均增加;(ii)28例中有12例仅在低araC浓度(0.06 - 1.0 μM)下增加;(iii)28例中有3例仅在高araC浓度(10 - 100 μM)下增加;(iv)28例中有5例在任何给定剂量水平下均未增加。因此,23例有反应的患者中有20例在低剂量或常规剂量araC(0.06 - 1.0 μM)下显示GM-CSF诱导araC掺入增强。GM-CSF后DNA聚合酶α活性升高(16 - 531%,中位数为72%)的18例中有14例,总体DNA聚合酶活性增强(10 - 70%,中位数为22.5%)的有10例。相比之下,GM-CSF后胸苷激酶(TK)和脱氧胞苷激酶(dCK)活性分别仅在10例和5例患者中升高。在21份骨髓标本中的11份以及9份外周原始细胞样本中的5份中发现S期细胞比例增加。然而,未观察到S期细胞比例增加与酶活性增强之间的相关性。在13例患者中,通过原始细胞集落测定评估了有或无GM-CSF时araC的细胞毒性。GM-CSF预孵育使13例患者中的10例araC介导的细胞毒性增加,中位数为3.2倍(范围为2.2 - 229倍)。araC各自的半数致死剂量(LD50)值平均从0.45 μM降至0.19 μM。(摘要截断于400字)